Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study

被引：0
|
作者：
Abbenante, Mariachiara [1 ]
Papayannidis, Cristina [1 ]
Iacobucci, Ilaria [1 ]
Candoni, Anna [2 ]
Paolini, Stefania [1 ]
Malagola, Michele [3 ]
Emanuela, Ottaviani [1 ]
Lonetti, Annalisa [1 ]
Curti, Antonio [1 ]
Parisi, Sarah [1 ]
Testoni, Nicoletta [1 ]
Lama, Barbara [1 ]
Baccarani, Michele [1 ]
Martinelli, Giovanni [1 ]
机构：
[1] Univ Bologna, Dept Hematol Oncol Seragnoli, Bologna, Italy
[2] Div Hematol & BMT, Udine, Italy
[3] Univ Brescia, Hematol & BMT Unit, Brescia, Italy
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.4M2011-2236
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2236
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Results of a Randomized Phase 2 Study of Clofarabine Plus Cytarabine (CA) Vs Clofarabine Plus Idarubicin (CI) Vs Clofarabine, Idarubicin, Plus Cytarabine (CIA) as Salvage Therapy in Acute Myeloid Leukemia (AML).
    Faderl, Stefan
    Borthakur, Gautam
    Ravandi, Farhad
    Huang, Xuelin
    Beran, Miloslav
    Ferrajoli, Alessandra
    Koller, Charles A.
    Thomas, Deborah A.
    Verstovsek, Srdan
    Kwari, Monica
    Kantarjian, Hagop M.
    BLOOD, 2008, 112 (11) : 354 - 355
  • [42] A PHASE 2 STUDY OF VORELOXIN AS SINGLE AGENT THERAPY FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
    Ravandi, F.
    Stuart, R.
    Maris, M.
    Stone, R.
    Cripe, L.
    Cooper, M.
    Turturro, F.
    Stock, W.
    Strickland, S.
    Mahadocon, K.
    Fox, J.
    Michelson, G.
    Berman, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 119 - 119
  • [43] Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia-Preliminary Results From a Phase I Study
    Uy, Geoffrey L.
    Avigan, David
    Cortes, Jorge E.
    Becker, Pamela S.
    Chen, Robert W.
    Liesveld, Jane L.
    Hewes, Becker
    Johns, Don
    Erba, Harry Paul
    BLOOD, 2011, 118 (21) : 39 - 40
  • [44] A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Bouligny, Ian M.
    Kantarjian, Hagop M.
    Yilmaz, Musa
    Daver, Naval
    Borthakur, Gautam
    Dinardo, Courtney D.
    Montalban-Bravo, Guillermo
    Short, Nicholas J.
    Valero, Yesid Alvarado
    Jabbour, Elias
    Jain, Nitin
    Pemmaraju, Naveen
    Hammond, Danielle
    Chien, Kelly S.
    Takahashi, Koichi
    Issa, Ghayas C.
    Abbas, Hussein A.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2024, 144 : 735 - 736
  • [45] A Phase I Study of Selinexor in Combination with Daunorubicin and Cytarabine in Patients with Newly Diagnosed Poor-Risk Acute Myeloid Leukemia
    Sweet, Kendra L.
    Komrokji, Rami S.
    Padron, Eric
    Cubitt, Christopher L.
    Khavarian, Leyla
    List, Alan F.
    Sallman, David
    Sullivan, Daniel
    Chavez, Julio C.
    Shah, Bijal D.
    Lancet, Jeffrey E.
    BLOOD, 2016, 128 (22)
  • [46] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
    Norbert Vey
    Hagop Kantarjian
    Miloslav Beran
    Susan O'Brien
    Jorge Cortes
    Charles Koller
    Elihu Estey
    Investigational New Drugs, 1999, 17 : 89 - 95
  • [47] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
    Vey, N
    Kantarjian, H
    Beran, M
    O'Brien, S
    Cortes, J
    Koller, C
    Estey, E
    INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) : 89 - 95
  • [48] Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
    Ravandi, Farhad
    Cortes, Jorge E.
    Jones, Daniel
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Konopleva, Marina Y.
    O'Brien, Susan
    Estrov, Zeev
    Borthakur, Gautam
    Thomas, Deborah
    Pierce, Sherry R.
    Brandt, Mark
    Byrd, Anna
    Bekele, B. Nebiyou
    Pratz, Keith
    Luthra, Rajyalakshmi
    Levis, Mark
    Andreeff, Michael
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1856 - 1862
  • [49] Phase II study of cladribine, idarubicin, cytarabine (CLIA) plus gilteritinib in patients (pts) with FLT3 mutated acute myeloid leukemia (AML).
    Abuasab, Tareq
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Bravo, Guillermo Montalban
    Valero, Yesid Alvarado
    Daver, Naval Guastad
    Yilmaz, Musa
    Pemmaraju, Naveen
    Chien, Kelly Sharon
    Kornblau, Steven Mitchell
    Burger, Jan Andreas
    Jain, Nitin
    Islam, Rabiul
    Dinardo, Courtney Denton
    Borthakur, Gautam
    Jabbour, Elias
    Ravandi, Farhad
    Kadia, Tapan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7+3) in newly diagnosed high-risk acute myeloid leukemia (AML)
    Zeidner, Joshua F.
    Foster, Matthew C.
    Blackford, Amanda L.
    Litzow, Mark R.
    Morris, Lawrence E.
    Strickland, Stephen A.
    Lancet, Jeffrey E.
    Bose, Prithviraj
    Levy, M. Yair
    Tibes, Raoul
    Gojo, Ivana
    Gocke, Christopher D.
    Rosner, Gary L.
    Little, Richard F.
    Wright, John J.
    Doyle, L. Austin
    Smith, B. Douglas
    Karp, Judith E.
    LEUKEMIA RESEARCH, 2018, 72 : 92 - 95
12345